Farallon steps up activism at biotech company Exelixis. Here's what could happen next

Farallon isn’t an activist investor, but it won’t shy away from a battle if necessary.

Related Keywords

Robert Oliver ,Tomas Heyman ,Acceleron Pharma ,David Johnson ,Carlyle Group ,Johnson ,Capital Allocation Committee ,Institutional Shareholder Services ,Caligan Partners ,Capital Allocation ,Investment Strategy ,Hedge Funds ,Exelixis Inc ,Business News ,